The average one-year price target for OKYO Pharma (NasdaqCM:OKYO) has been revised to $10.20 / share. This is an increase of 25.00% from the prior estimate of $8.16 dated April 25, 2026.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $7.07 to a high of $13.65 / share. The average price target represents an increase of 529.63% from the latest reported closing price of $1.62 / share.
What is the Fund Sentiment?
There are 12 funds or institutions reporting positions in OKYO Pharma. This is unchanged over the last quarter. Average portfolio weight of all funds dedicated to OKYO is 0.07%, an increase of 77.96%. Total shares owned by institutions decreased in the last three months by 73.30% to 713K shares.
What are Other Shareholders Doing?
Dauntless Investment Group holds 472K shares representing 0.90% ownership of the company. In its prior filing, the firm reported owning 2,422K shares , representing a decrease of 413.66%. The firm decreased its portfolio allocation in OKYO by 80.44% over the last quarter.
Renaissance Technologies holds 138K shares representing 0.26% ownership of the company. In its prior filing, the firm reported owning 41K shares , representing an increase of 70.14%.
UBS Group holds 60K shares representing 0.11% ownership of the company. In its prior filing, the firm reported owning 2K shares , representing an increase of 96.37%. The firm increased its portfolio allocation in OKYO by 269.69% over the last quarter.
XTX Topco holds 18K shares representing 0.03% ownership of the company.
Cerity Partners holds 13K shares representing 0.02% ownership of the company. No change in the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
